Literature DB >> 19016746

Identification of mitochondrial F(1)F(0)-ATP synthase interacting with galectin-3 in colon cancer cells.

Duck-Woo Kim1, Kyung Hee Kim, Byong Chul Yoo, Sung-Hye Hong, Yong Chul Lim, Young-Kyoung Shin, Jae-Gahb Park.   

Abstract

To evaluate the effect of galectin-3 in cell cycle regulation of colon cancer cells, we looked for binding molecules interacting with galectin-3 and examined the changes in cell cycle by suppressing galectin-3 and the binding molecule. To identify target molecules interacting with galectin-3, we analyzed immunoprecipitate of the anti-galectin-3 antibody obtained from human colon cancer cell line, using matrix-assisted laser desorption ionization-mass spectrometry. We validated subcellular localization of galectin-3 and ATP synthase identified, and ATP synthase activity was determined in the presence of galectin-3. Cell cycle regulation was monitored after galectin-3 siRNA transfection. ATP synthase b-subunit was identified in immunoprecipitate of the anti-galectin-3 antibody. Galectin-3 and ATP synthase were co-isolated in the inner membrane vesicles of mitochondria. Galectin-3 has an inhibitory activity against ATP synthase, and intracellular ATP content showed increasing tendency after galectin-3 suppression. Suppression of galectin-3 resulted in G0/G1 progression of human colon cancer cells arrested at S, S/G2 and G2/M phase in the presence of doxorubicin, and etoposide or nocodazole, respectively. Compared to cells in which ATP synthase d-subunit was suppressed alone, sub-G1 fraction caused by etoposide or nocodazole was decreased in cells with galectin-3 suppression alone. In conclusion, galectin-3 co-localized with ATP synthase in the inner membrane of mitochondria and has an inhibitory effect on ATP synthase in human colon cancer cells. In the presence of cell cycle synchronizing drugs, doxorubicin, etoposide, or nocodazole, suppression of galectin-3 induced cell cycle progression to G0/G1 phase.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19016746     DOI: 10.1111/j.1349-7006.2008.00901.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  6 in total

Review 1.  Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure.

Authors:  Diego José Laderach; Daniel Compagno
Journal:  Cancers (Basel)       Date:  2021-09-09       Impact factor: 6.575

2.  ANGT_HUMAN[448-462], an Anorexigenic Peptide Identified Using Plasma Peptidomics.

Authors:  Sayaka Sasaki; Kazuhito Oba; Yoshio Kodera; Makoto Itakura; Masayoshi Shichiri
Journal:  J Endocr Soc       Date:  2022-05-19

3.  Galectin-3 up-regulation in hypoxic and nutrient deprived microenvironments promotes cell survival.

Authors:  Rafael Yamashita Ikemori; Camila Maria Longo Machado; Karina Mie Furuzawa; Suely Nonogaki; Eduardo Osinaga; Kazuo Umezawa; Marcelo Alex de Carvalho; Liana Verinaud; Roger Chammas
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

4.  Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity.

Authors:  Gema Marín-Royo; Isabel Gallardo; Ernesto Martínez-Martínez; Beatriz Gutiérrez; Raquel Jurado-López; Natalia López-Andrés; Josué Gutiérrez-Tenorio; Eduardo Rial; Marı A Visitación Bartolomé; María Luisa Nieto; Victoria Cachofeiro
Journal:  Dis Model Mech       Date:  2018-02-05       Impact factor: 5.758

5.  Metabolism under hypoxia in Tm1 murine melanoma cells is affected by the presence of galectin-3, a metabolomics approach.

Authors:  Pedro Starzynski Bacchi; Antonio Carlos Bloise; Silvina Odete Bustos; Lara Zimmermann; Roger Chammas; Said Rahnamaye Rabbani
Journal:  Springerplus       Date:  2014-08-26

6.  Galectin-3 modulates epithelial cell adaptation to stress at the ER-mitochondria interface.

Authors:  Lucie Coppin; Arnaud Jannin; Emilie Ait Yahya; Caroline Thuillier; Céline Villenet; Meryem Tardivel; Antonino Bongiovanni; Cécile Gaston; Simon de Beco; Nicolas Barois; Isabelle van Seuningen; Emmanuelle Durand; Amélie Bonnefond; Jean-Claude Vienne; Joseph Vamecq; Martin Figeac; Audrey Vincent; Delphine Delacour; Nicole Porchet; Pascal Pigny
Journal:  Cell Death Dis       Date:  2020-05-12       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.